Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Barron Von Hymen who wrote (286)	3/9/1998 12:37:00 AM
From: JAMES BORECKI	Read Replies (1) \| Respond to of 1321

Barron, Thank you for the clarification. I was quite upset when I first misinterpreted the comment. Goos luck and good judgement, JimB

To: Barron Von Hymen who wrote (286)	3/22/1998 12:54:00 PM
From: John O'Neill	Read Replies (1) \| Respond to of 1321

I new to the thread..the article discussing frequents of light (630 vs 730) the end reads...... Furthermore, tissue treated with 730 nm light alone (without PHOTOFRIN(R)) showed no detectable adverse effect. These results were made possible using Photogen's proprietary simultaneous two-photon activation process, which allows use of activation wavelengths that more easily penetrate tissue. Photogen's activation process further enables three dimensional control over the activation site.>> What is "Photogen"? part of QLTIF??do they have the "proprietary tech?) JO